Welcome to our dedicated page for Actuate Therapeutics SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elraglusib鈥檚 journey from lab bench to clinic means Actuate Therapeutics鈥� SEC disclosures are packed with dense data on GSK-3尾 science, trial cohorts, and cash runway projections鈥攄etails critical for biotech investors yet hard to digest quickly.
Problem: Finding the latest dose-limiting toxicity update inside a 300-page 10-K or spotting a sudden insider stock sale before a Phase 2 read-out can take hours. Solution: Stock Titan鈥檚 AI-powered platform turns every Actuate Therapeutics filing into an executive-level brief. Our engine highlights clinical-trial milestones, R&D spend, and partnership terms, then links them to market-moving events.
Access every document the moment it hits EDGAR: 10-K annual reports, 10-Q quarterly earnings, 8-K material events, S-1 fundraising prospectuses, and real-time Form 4 insider trades. Investors searching for 鈥淎ctuate Therapeutics insider trading Form 4 transactions鈥� or 鈥淎ctuate Therapeutics quarterly earnings report 10-Q filing鈥� land here because we answer those questions directly. Want the proxy statement executive compensation breakdown? It鈥檚 parsed and summarised. Need 鈥淎ctuate Therapeutics 8-K material events explained鈥�? Our AI does that, too.
Practical use cases include:
- Monitoring 鈥淎ctuate Therapeutics Form 4 insider transactions real-time鈥� to gauge management sentiment.
- Reviewing 鈥淎ctuate Therapeutics earnings report filing analysis鈥� to compare cash burn across quarters.
- Downloading an 鈥淎ctuate Therapeutics annual report 10-K simplified鈥� to understand pipeline risk factors without legalese.
Actuate Therapeutics (NASDAQ:ACTU) entered a $4.7 million private placement with institutional and accredited investors, selling 666,497 common shares at $7.00 and issuing 666,497 cash-only warrants at the same price. Warrants are immediately exercisable and expire 20 days after an FDA milestone (Breakthrough Therapy designation or Phase 2/3 registration pathway feedback), potentially providing another $4.7 million.
Closing is expected by June 30 2025; proceeds earmarked for working capital. Bios 2024 Co-Invest will hold ~49.9 % beneficial ownership post-deal. A Registration Rights Agreement requires ACTU to file a resale shelf by August 9 2025 and meet strict effectiveness deadlines, with liquidated damages for failure.
- Item 1.01: Securities Purchase & Warrants
- Item 3.02: Unregistered sales under Reg D
- Going-concern risk remains despite new funding.
FAQ
What is the current stock price of Actuate Therapeutics (ACTU)?
What is the market cap of Actuate Therapeutics (ACTU)?
